Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 21,191 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated Phase 1 Interventional

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

NCT01910428
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
L-asparaginase encapsulated in RBC
Drug
Lead sponsor
ERYtech Pharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Lake Success, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 19, 2026, 3:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study and Treatment of Inflammatory Muscle Diseases

NCT00001265
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
16 Years and older
Enrollment
1,325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 19, 2026, 3:15 PM EDT
Withdrawn Phase 2 Interventional

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

NCT00298467
View directory record Official record
Conditions
Lymphoma, Large-Cell
Interventions
MDX-060
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Duarte, California • Fresno, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Oct 19, 2026, 3:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

NCT01966367
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions
CD34 Stem Cell Selection Therapy
Biological
Lead sponsor
Diane George
Other
Eligibility
Up to 40 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

NCT01301807
View directory record Official record
Conditions
Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Panobinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Overdose Risk Among Recently Incarcerated People Living With HIV/AIDS

NCT03569592
View directory record Official record
Conditions
Drug Overdose Accidental
Interventions
Overdose Prevention Intervention
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 19, 2026, 3:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT07468136
View directory record Official record
Conditions
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma, Glioblastoma, IDH-Wildtype, Malignant Glioma
Interventions
Biospecimen Collection, Eflornithine, Lumbar Puncture, Magnetic Resonance Imaging, Retifanlimab, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems

NCT02283411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Abbott Sensor Based Glucose Monitoring System
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Santa Barbara, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00593944
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
MDX-1342
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation

NCT00441844
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Simvastatin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 19, 2026, 3:15 PM EDT
Not listed Phase 4 Interventional

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00005000
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
0 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 3:15 PM EDT
Recruiting No phase listed Observational

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

NCT07313592
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 3:15 PM EDT
Completed No phase listed Observational

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV

NCT06205511
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papilloma Virus
Interventions
Oral HPV Sample
Diagnostic Test
Lead sponsor
Vivent Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 3:15 PM EDT
Terminated Phase 2 Interventional Results available

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

NCT05086744
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Not applicable Interventional

Distant Healing for HIV/AIDS

NCT00079534
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Non-local/distant healing or prayer
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 19, 2026, 3:15 PM EDT
Withdrawn No phase listed Observational

Long-term Registry of Patients Treated With Loncastuximab Tesirine

NCT05160064
View directory record Official record
Conditions
B-Cell Lymphomas
Interventions
Not listed
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 3:15 PM EDT
Not listed Phase 2 Interventional

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

NCT04850664
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity
Interventions
CBOT + TAU, Sham + TAU
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 19, 2026, 3:15 PM EDT
Recruiting Phase 3 Interventional

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

NCT07067463
View directory record Official record
Conditions
Multiple Sclerosis (MS) Primary Progressive
Interventions
Orelabrutinib, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 19, 2026, 3:15 PM EDT
Terminated Phase 1 Interventional

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

NCT01742793
View directory record Official record
Conditions
Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions
lenalidomide (Revlimid) and romidepsin (Istodax)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 4 Interventional

DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

NCT00116116
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
efavirenz, stavudine extended release, lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
10
States / cities
Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 19, 2026, 3:15 PM EDT
Completed No phase listed Observational

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

NCT00490906
View directory record Official record
Conditions
Multiple Sclerosis, Low Bone Density
Interventions
Copaxone, Interferon-beta 1a, Interferon-beta 1b
Drug
Lead sponsor
Nancy Hammond, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 19, 2026, 3:15 PM EDT
Completed Phase 1 Interventional

Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)

NCT00028236
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Gene-Transduced Autologous CD34+ Stem Cells
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 20 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 3:15 PM EDT